Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 7;10:16758. doi: 10.1038/s41598-020-73815-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Results of the PET assessments. Blue circles represent baseline PET examinations and red squares represent follow-up PET examinations on treatment with 0.2 or 0.12 mg SAR425899. Liver binding of [⁶⁸Ga]Ga-DO3A-Tuna-2, corrected for plasma glucagon levels and decrease in liver volume, at baseline and on SAR425899 treatment (A). [⁶⁸Ga]Ga-DO3A-Exendin-4 binding in pancreas at baseline and follow-up (B). The uncorrected [⁶⁸Ga]Ga-DO3A-Tuna-2 liver binding (C) and following correction only for the change in liver volume (D) is also shown for clarity of the analysis. Percentages indicate change in binding, i.e. occupancy of SAR425899 treatment compared to baseline.